Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/680041


Hong Kong Pharmaceuticals and Healthcare Report Q4 2008


Description: Hong Kong Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Hong Kong's pharmaceuticals and healthcare industry.

Compared to the Q308 report, the value of Hong Kong’s pharmaceutical market at the end of our forecast period has increased fractionally, from US$1.177bn to US$1.184bn. The reason behind the 0.6% rise is revised macroeconomic figures provided by our Country Risk team, which in turn influences our Drug Expenditure Forecast Model. Because we use a top-down approach, this amendment in turn reflects on the five-year projections for patented products, generic drugs and over-the-counter (OTC) medicines. Hong Kong’s pharmaceutical industry consists of about 190 manufacturing firms, of which 40 are licensed to manufacture mainly generic ‘Western’ drugs.

Domestic capacity appears to be shrinking, or at least consolidating, with figures showing 46 licensed drugmakers in 2007, compared with 48 in 1999, 54 in 1998 and 86 in 1993. Domestic output is small scale, and includes Chinese medicines and consumer health products, as well as prescription drugs. There are only a handful of domestic companies with significant manufacturing capabilities. One such example is United Laboratories International Holdings (TUL), which specialises in finished products, bulk medicine, intermediates and capsules.

Appreciating the burden of influenza, the government announced in July 2008 that it would launch a subsidised vaccination programme. Under the scheme, each eligible child will receive a HKD80 (US$10.30) subsidy to receive a shot from participating private doctors. The programme will cost HKD56mn (US$6.8mn) in total. In July 2008, Dr York Chow, Secretary for Food & Health in Hong Kong, dismissed claims that the government was ignoring ‘bottlenecks’ in the healthcare system as it looks to implement mandatory insurance. Chow called for ‘whole system reform’, stressing that a balance was required while easing the burden on the public health sector to handle bottlenecks.

The Special Administrative Region (SAR)’s R&D-based industry association, the Hong Kong Association of the Pharmaceutical Industry (HKAPI), said in July 2008 that it remained cautious towards the planned reforms of the public healthcare sector. Specifically, it wanted to see the adoption of a more evidence-based approach to healthcare, which is a trend that we are seeing globally.


Contents: Executive Summary
Hong Kong Pharmaceuticals And Healthcare Industry SW
Hong Kong Political SWOT
Hong Kong Economic SWOT
Hong Kong Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Asia Pacific Pharmaceuticals & Healthcare Business Environment Rankings For Q408
Limits Of Potential Returns
Risks To Realisation Of Returns
Hong Kong – Market Summary
Regulatory Regime
Intellectual Property Issues
Counterfeit Drugs
Pricing And Reimbursement Developments
Industry Trends And Developments
Epidemiology
Healthcare Sector
Table: Secondary/Tertiary Public Sector Health Services In Hong Kong
Healthcare Sector Reforms
Healthcare Financing
Hospital Pharmacy Sector
Public Procurement Of Medicines
Pharmaceutical Industry
Traditional Chinese Medicines
Foreign Industry Developments
Research And Development
Medical Devices
Table: Examples Of Medical Devices
Supply Chain
Overall Market Forecast
Table: Drug Expenditure And Prescription Market ATC Breakdowns (US$mn unless otherwise stated)
Key Growth Factors – Industry
Table: Hong Kong’s Health Expenditure Forecast
Key Growth Factors – Macroeconomic
Table: Hong Kong – Economic Activity
Patented Drug Market Forecast
Table: Hong Kong’s Patented Drug Market Forecast
Generic Drug Market Forecasts
Table: Hong Kong’s Generic Drug Market Forecast
OTC Market Forecast
Table: Hong Kong’s OTC Market Forecast (US$mn unless otherwise stated)
Export/Import Forecasts
Table: Hong Kong Pharmaceuticals Export/Import (US$mn)
Other Healthcare Data And Forecasts
Table: Hong Kong’s Hospital Data Forecasts
Key Risks To BMI’s Forecast Scenario
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Table: Hong Kong’s Leading Drugmakers And Products, Q406
Company Profiles
Leading Multinational Companies
GlaxoSmithKline
Pfizer
Sanofi-Aventis
Merck & Co
Novartis
Local Pharmaceutical Companies
Wuyi International Pharmaceutical
CK Life Sciences
South Asia Pharmamedic Ltd
C&Y Pharmaceutical Investment Holding
Vida Laboratories
Country Snapshot: Hong Kong Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2005-2012
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources


Companies Mentioned -GlaxoSmithKline -Pfizer -Sanofi-Aventis -Merck & Co -Novartis -Wuyi International Pharmaceutical -CK Life Sciences -South Asia Pharmamedic Ltd -C&Y Pharmaceutical Investment Holding -Vida Laboratories


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/680041

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 26/11/2009 21:29:04
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Hong Kong Pharmaceuticals and Healthcare Report Q4 2008
Web Address:
http://www.researchandmarkets.com/reports/680041
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €440.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 26/11/2009 21:29:04

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)